Landcent announces an investment opportunity for the times

Landcent Europe B.V. is announcing an effort to raise a total of €7.5m between Q1 2021 and end 2022 to finalize the rollout of its products. €2.5m of equity is currently sought for 10% of the company pre-money.

Landcent has previously caught the attention of major tech investors such as Shan Xiangshuang - whose Hone Capital is one of Silicon Valley’s biggest funds - and the Bill & Melinda Gates Foundation, both who have contributed to the €10.21 million secured to date. We are now offering a 10% stake in the company (pre-money) which will provide investors not only with the potential for sizeable estimated returns but also precise and measurable social impact. Over the next decade Landcent's products could save up to 2.1 million lives and avert over 600 million cases of malaria.

Unlike any other company in the world, Landcent is a specialist in all three key WHO recommended malaria prevention technologies: treated bed-nets, indoor residual spraying (IRS) and preventive antimalarial pills that are safe for pregnant women and children to use. The three preventative solutions are normally siloed between different industries - with textile, agrochemical and pharmaceutical companies developing technologies separately rather than coordinating their efforts and sharing learnings. Landcent‘s unique approach brings together these specialisms.

Our next-generation bed net and IRS technology harnesses an existing WHO-approved chemical compound within a patented innovative micro-encapsulation technology that releases the chemical slowly over a long period of time. This innovative work has led Landcent to become a member of the World Health Organization's Global Collaboration for Development of Pesticides for Public Health (GCDPP).

In 2022 when Landcent begins global distribution of its products, the combined malaria prevention market estimated to be worth $2.4 billion, is expected to grow to $4 billion by 2030.

Arun Prabhu Stanley, Co-Founder and Vice President of Landcent comments:

“This public investment round aims to unlock the final two years of our journey towards a new range of products that could disrupt the significant malaria prevention market. Initial product trials have been very successful and health ministries from Nigeria, Kenya and Liberia have expressed their gratitude for innovation in this area and keen anticipation for the solutions due to be rolled out in 2022.”

He continues: “COVID-19 is posing a fundamental threat to the progress against malaria and other infectious diseases, threatening a catastrophic rise in the number of deaths and infections. All of this reestablishes the importance of public health innovators like Landcent, who are committed to last mile delivery.”

Email us if you are interested in investing with Landcent and joining the fight against malaria.